Steris to acquire Xodus Medical in a $2.1 billion cash deal
Steris plc announced a definitive agreement to buy Xodus Medical for $2.1 billion, with a net purchase price of about $1.8 billion after expected cash tax benefits. The transaction includes up to $150 million of performance‑based earnout payments and is slated to close by 31 December 2026, subject to regulatory approval. Xodus projects 2026 revenue of $245 million and adjusted EBIT of $135 million, adding to Steris’s consumables portfolio.
Why it matters
TipRanks analysts rate STE as a Buy and set a $269 price target, citing the acquisition’s accretive potential and Steris’s strong financial quality. The debt‑financed deal will increase leverage but is expected to boost earnings per share from 2027 onward.
Key facts
- 1Steris agreed to acquire Xodus Medical for $2.1 billion in cash. tradingview.com
- 2The net purchase price is reduced to approximately $1.8 billion after cash tax benefits of roughly $300 million. investing.com
- 3Up to $150 million of additional earnout consideration is tied to Xodus performance targets in calendar 2028. financial-news.co.uk
- 4The acquisition is expected to close by 31 December 2026, pending regulatory approvals. tradingview.com
- 5Xodus projects 2026 revenue of $245 million. tradingview.com
- 6Xodus projects adjusted EBIT of $135 million for 2026. tradingview.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.